Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Combination Treatment	STARTED	GP2013	312
Combination Treatment	STARTED	Rituximab	315
Combination Treatment	COMPLETED	GP2013	274
Combination Treatment	COMPLETED	Rituximab	274
Combination Treatment	NOT COMPLETED	GP2013	38
Combination Treatment	NOT COMPLETED	Rituximab	41
Maintenance Treatment and/or Follow up	STARTED	GP2013	254
Maintenance Treatment and/or Follow up	STARTED	Rituximab	252
Maintenance Treatment and/or Follow up	COMPLETED	GP2013	132
Maintenance Treatment and/or Follow up	COMPLETED	Rituximab	150
Maintenance Treatment and/or Follow up	NOT COMPLETED	GP2013	122
Maintenance Treatment and/or Follow up	NOT COMPLETED	Rituximab	102
Open Label Phase	STARTED	GP2013	44
Open Label Phase	STARTED	Rituximab	39
Open Label Phase	COMPLETED	GP2013	43
Open Label Phase	COMPLETED	Rituximab	38
Open Label Phase	NOT COMPLETED	GP2013	1
Open Label Phase	NOT COMPLETED	Rituximab	1

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01419665/flow